Alligator Bioscience Logo
SE0024173637
A41BED

Alligator Bioscience

Chargement des cours...

Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Alligator Bioscience stops Mitazalimab development, stock plunges 74%

    Alligator Bioscience’s board has halted further independent development of the CD40 antibody Mitazalimab due to the rapidly changing treatment landscape in pancreatic cancer and intends to out-license or sell the drug. Resources will be redirected to HLX22 (anti-HER2), which is being developed externally by Shanghai Henlius Biotech; Alligator will receive revenue participation for this without development expense. The company also announced a rights issue of around SEK 125.6 million and a bridge financing; cash of SEK 33 million will only last until mid-Q3 2026. The combination of the project halt, a heavily dilutive capital measure and strained liquidity triggered the sharp share price decline. » Plus sur de.investing.com


  • Alligator Bioscience cuts costs sharply and plans phase‑III start for mitazalimab

    Alligator Bioscience reports significant cost reductions in Q1 2026 (annualized operating costs cut from 300 to 100 million SEK; Q1 costs 17 million SEK) and reports cash of 33 million SEK. Lead candidate mitazalimab showed a 30‑month survival rate of 20% in Phase II, and the company is preparing to start a Phase‑III trial in Q4 2026; a regulatory submission is expected in Q2 2026. Because cash is only expected to last until mid‑Q3 2026, Alligator is actively exploring financing options. The stock rose 4.69% following the results. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, Alligator Bioscience a réalisé un chiffre d'affaires de 20,9 k € et un bénéfice net de -1,47 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 20,9 k 50,63 %
Bénéfice brut -1,31 M -
Bénéfice net -1,47 M 32,53 %
EBITDA -1,72 M 155,43 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
41,96 k €
Nombre d'actions
53,09 M
Plus haut/bas sur 52 semaines
0,11 € - 0,000781 €
Dividendes Non
Bêta
1,17
Ratio P/E
-0,01
Ratio PEG
0,00
Ratio P/B
0,24
Ratio P/S
1,65

Profil de l'entreprise

Nom
Alligator Bioscience
PDG
Søren Bregenholt
Employés 11
🍪

Parqet  utilise des cookies. En savoir plus